NEW YORK: Scientists at the U.S. Food and Drug Administration (FDA) said on Friday that the likely benefits of giving the Pfizer/BioNTech COVID-19 vaccine to 5 to 11 year olds clearly outweigh the risks of rare cases of heart inflammation.
Earlier on Friday, the vaccine makers said their shot showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old.
The details were in briefing documents published ahead of a meeting of a panel of outside experts scheduled to vote on Tuesday whether to recommend the FDA authorize the shots for the young age group.
If the FDA authorizes the Pfizer/BioNTech immunization for children 5 to 11 years old, it would be the first COVID-19 vaccine for the age group and shots could be available in the United States in early November.
Both the Pfizer/BioNTech and Moderna Inc vaccines have been linked to rare cases of heart inflammation called myocarditis, especially in young men.
The FDA staff said that, assuming the number of myocarditis cases observed in the younger age group would be similar to that seen in 12 to 15 year olds, the number of COVID-19 related hospitalizations prevented would outnumber myocarditis-related hospitalizations in most scenarios analyzed.
Pfizer suggested in its own briefing documents that the rate of myocarditis in the age group was likely to be lower than observed in vaccinated 12 to 15 year olds, in part because the younger children were given a lower dose.
The 5 to 11 year olds were given two shots of a 10-microgram dose, a third of what was given to people 12 years and older.
Sixteen children in the trial who had received a placebo got COVID-19, versus three who were vaccinated, Pfizer said in briefing documents submitted to the FDA.
Because more than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy.
Pfizer's clinical trial in those 5 to 11 years old was not primarily designed to measure efficacy against the virus.
Instead, it compared the amount of neutralizing antibodies induced by the vaccine in the children to the response of older recipients in their adult trial.
Based on those results, Pfizer and BioNTech said last month that their COVID-19 vaccine induced a robust immune response in the children. The FDA staff said the vaccine met the agency's criteria for the immune response it generated in the children.
EXPANDED TRIAL
Pfizer also said on Friday that it had expanded its clinical trial to improve its safety data, more than doubling the number of children enrolled.
According to Pfizer, the adverse event profile in the expanded group did not suggest any new safety concerns from the vaccine. The company had said previously that the safety profile in the age group was generally comparable to 16 to 25 year olds.
The second cohort of children have been observed for a shorter time. All of them had received their second dose and more than 70% were more than two weeks post dose two.
The Pfizer/BioNTech vaccine already has U.S. regulatory authorization for people who are at least 12 years old, including full FDA approval in August for those 16 and up.
Around 190 million people in the United States are fully vaccinated, including more than 11 million who are 12 to 17 years old that have received the Pfizer vaccine.
If the FDA authorizes the vaccine for 5 to 11 year olds, a group of advisers to the U.S. Centers for Disease Control and Prevention (CDC) will meet on Nov. 2-3 to make recommendations to the agency on how the shots should be administered.
Most states wait for the CDC to sign off on recommendations for vaccines before they begin administering shots.
Reuters
Sat Oct 23 2021
![FDA says benefits outweigh risks for Pfizer-BioNTech COVID-19 vaccine in children FDA says benefits outweigh risks for Pfizer-BioNTech COVID-19 vaccine in children](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-12/51608771433_TBVACCINEPFIZER.jpg)
The vaccine makers said their shot showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old. - REUTERS/Dado Ruvic/Illustration/File Photo
Mpox atau cacar monyet: WHO isytihar mpox kecemasan kesihatan awam global
Pertubuhan Kesihatan Sedunia (WHO) mengisytiharkan Monkeypox atau Mpox sebagai kecemasan kesihatan awam global, pada Rabu.
Parlimen Thailand pilih perdana menteri baharu Jumaat ini
Parlimen Thailand akan bersidang pada Jumaat ini bagi mengadakan mesyuarat khas memilih perdana menteri baharu susulan keputusan mahkamah yang menyingkirkan Srettha Thavisin pada Rabu/
![Parlimen Thailand pilih Perdana Menteri baharu esok Parlimen Thailand pilih Perdana Menteri baharu esok](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/71723695263_TBSretthaThavisin.jpg)
Parlimen Thailand pilih Perdana Menteri baharu esok
Parlimen Thailand akan bersidang pada Jumaat ini bagi mengadakan mesyuarat khas memilih perdana menteri baharu susulan keputusan mahkamah yang menyingkirkan Srettha Thavisin pada Rabu.
5 kematian akibat komplikasi denggi pada ME ke 31 dilaporkan
Jumlah kes demam denggi Pada Minggu Epidemiologi ke-31 tahun 2024 dilaporkan sebanyak 2,515 kes berbanding 2,609 kes pada minggu sebelumnya.
[TERKINI] Fahmi nafi arah Google nyahaktif ciri graf penukar ringgit
Menjawab tuduhan seorang pengguna X, Ahli Parlimen Lembah Pantai itu menerusi platform sama menegaskan beliau tidak pernah mengarahkan penyedia perkhidmatan itu berbuat demikian.
![Wanita dan kanak-kanak maut dalam nahas kereta, MPV di Kuala Kangsar Wanita dan kanak-kanak maut dalam nahas kereta, MPV di Kuala Kangsar](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/51723694795_KemalanganMaut.jpg)
Wanita dan kanak-kanak maut dalam nahas kereta, MPV di Kuala Kangsar
Dua maut selepas kereta dinaiki terlibat dalam kemalangan dengan sebuah MPV jenis Toyota Velfire di Jalan Kuala Kangsar-Manong.
[TERKINI] Bapa terima baik kehilangan Nidza Afham
Mokhtar Mahmud, bapa kepada penyanyi Muhammad Nidza Afham redha dengan pemergian Allahyarham yang disahkan meninggal dunia selepas jasadnya ditemui terapung di jambatan Sungai Klang pada petang Rabu.
Pantau Belanjawan: Kelestarian: Memperkukuh ekosistem ekonomi hijau
Pengarah Urusan Gading Kencana, Datuk Ir Guntor Tobeng mengulas berkenaan usaha Malaysia memperkukuh ekosistem ekonomi hijau, di sebalik cabaran global serta peluang masa hadapan.
[TERKINI] Belasungkawa: Nidza Afham dikebumikan di Puncak Alam
Jenazah penyanyi Nidza Afham Mokhtar, 23, yang ditemukan meninggal dunia di Sungai Klang, akan dikebumikan di Tanah Perkuburan Islam, Puncak Alam, Selangor, pada Khamis.
![EON Berhad mahu dikenali sebagai penyedia perkhidmatan automotif menyeluruh EON Berhad mahu dikenali sebagai penyedia perkhidmatan automotif menyeluruh](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/81723694796_EON.jpg)
EON Berhad mahu dikenali sebagai penyedia perkhidmatan automotif menyeluruh
EON Berhad sedang memposisikan diri sebagai lebih daripada sekadar penyedia kereta, dengan berkembang menjadi penyedia perkhidmatan kereta secara menyeluruh.
![Pengeluar vaksin Biontech didakwa di mahkamah Jerman berhubung pertikaian paten Pengeluar vaksin Biontech didakwa di mahkamah Jerman berhubung pertikaian paten](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2023-08/71691468736_TBCourtHammer.jpg)
Pengeluar vaksin Biontech didakwa di mahkamah Jerman berhubung pertikaian paten
Curevac menyaman pesaingnya, Biontech untuk mendapatkan ganti rugi, dengan menuduh pengeluar utama vaksin Covid-19 itu melakukan pelanggaran paten.
![Vaksin Pfizer kanak-kanak bawah 5 tahun dijangka siap akhir Februari Vaksin Pfizer kanak-kanak bawah 5 tahun dijangka siap akhir Februari](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-02/81643707358_Pfizer.jpg)
Vaksin Pfizer kanak-kanak bawah 5 tahun dijangka siap akhir Februari
Pfizer dan BioNTech dijangka memohon untuk penggunaan kecemasan vaksin COVID-19 untuk kanak-kanak bawah 5 tahun.
![Berita antarabangsa pilihan sepanjang hari ini Berita antarabangsa pilihan sepanjang hari ini](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-08/71627747962_BAP.jpg)
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
![COVID-19: Tiga vaksin buatan Thailand tunjuk hasil memberangsangkan COVID-19: Tiga vaksin buatan Thailand tunjuk hasil memberangsangkan](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-07/81626271520_VaksinCOVID.jpg)
COVID-19: Tiga vaksin buatan Thailand tunjuk hasil memberangsangkan
Tiga vaksin COVID-19 yang dibangunkan di Thailand, termasuk satu menggunakan RNA messenger (mRNA), dijangka tersedia menjelang tahun depan.
![Kadar vaksinasi Malaysia antara terpantas di dunia, lapor The Sydney Morning Herald Kadar vaksinasi Malaysia antara terpantas di dunia, lapor The Sydney Morning Herald](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-07/51626154176_KhairyJamaluddin.jpg)
Kadar vaksinasi Malaysia antara terpantas di dunia, lapor The Sydney Morning Herald
Ia meletakkan program vaksinasi Malaysia sebaris dengan negara-negara maju lain seperti Kanada dan Australia.
![Vaksin COVID-19: Dos ketiga boleh datangkan kesan sampingan lebih buruk - CDC AS Vaksin COVID-19: Dos ketiga boleh datangkan kesan sampingan lebih buruk - CDC AS](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-07/51626164911_Vaccine.jpg)
Vaksin COVID-19: Dos ketiga boleh datangkan kesan sampingan lebih buruk - CDC AS
Lebih banyak data diperlukan untuk mengetahui sama ada dos tambahan boleh meningkatkan risiko kesan sampingan.
![COVID-19: Kes meningkat di Asia Tenggara bahang varian Delta COVID-19: Kes meningkat di Asia Tenggara bahang varian Delta](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-07/61625828809_WatPhraSiMahathat.jpg)
COVID-19: Kes meningkat di Asia Tenggara bahang varian Delta
Pakar kesihatan memberi amaran kadar ujian saringan yang rendah di negara berpopulasi tinggi seperti Indonesia dan Filipina menyukarkan pengesanan angka sebenar kes jangkitan.
![Varian Delta: Pfizer rancang minta kelulusan suntikan dos ketiga vaksin Varian Delta: Pfizer rancang minta kelulusan suntikan dos ketiga vaksin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-06/81623413031_vaccine.jpg)
Varian Delta: Pfizer rancang minta kelulusan suntikan dos ketiga vaksin
Terdapat bukti wujud risiko jangkitan semula yang lebih tinggi setelah enam bulan menerima suntikan.
![Berita antarabangsa pilihan sepanjang hari ini Berita antarabangsa pilihan sepanjang hari ini](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-04/51617796933_BAP.jpg)
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
![COVID-19: Amerika Syarikat sumbang 500 juta dos vaksin kepada negara miskin COVID-19: Amerika Syarikat sumbang 500 juta dos vaksin kepada negara miskin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-03/81617056527_JoeBiden.jpg)
COVID-19: Amerika Syarikat sumbang 500 juta dos vaksin kepada negara miskin
Amerika sebelum ini berdepan tekanan supaya meningkatkan akses vaksin kepada negara berpendapatan rendah.